drugset / Trial / NCT03960606

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

NCT03960606

Phase 2 Terminated 7 enrolled Pulmatrix Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

Timeline

Start
2019-07-31
Primary completion
2020-07-14
Completion
2020-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 10 mg Oral
Subject Itraconazole Small molecule 20 mg Oral
Subject Itraconazole Small molecule 35 mg Oral